IDH2 and neoplasm: It is, therefore, tempting to speculate that the JmjC-type KDM inhibitor 2-HG, which is the product of a tumor-associated gain of function mutation in IDH genes [see Histone and DNA (De)methylation], may alter repair efficiency in tumor cells.